Immunological assessment of SARS-CoV-2 in IENIMINI cohort individuals with influenza like symptoms.

Immunological assessment of SARS-CoV-2 in IENIMINI cohort individuals with influenza like symptoms. - Antibodies against SARS-CoV-2 in IENIMINI cohort individuals

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54879

Enrollment

560

Registered

2020-01-08

Start date

2021-03-29

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19 infection caused by SARS-CoV-2 virus

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - 18 years or older - participant of the IENIMINI cohort - reported influenza like symptoms in March-November 2020

Exclusion criteria

Exclusion criteria: No participant of the IENIMINI study.

Design outcomes

Primary

Measure	Time frame
The main study parameter is the seroprevalence of COVID19 in patients with an IMID & control persons who experienced influenza like symptoms in March-November 2020.	—

Secondary

Measure	Time frame
The secondary parameter is the difference between percentage of people with antibodies against COVID19 who experienced severe symptoms versus only mild symptoms.	—

Countries

Netherlands

Outcome results